Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease

Pharmacology and Therapeutics

Volumn 111, Issue 3, 2006, Pages 893-908

  Chapman, M John ^a,b  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

Atherosclerosis; Coronary heart disease; HDL cholesterol; Therapeutic elevation

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; APOLIPOPROTEIN; APOLIPOPROTEIN A1; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; COLESTYRAMINE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; GLITAZONE DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; SIMVASTATIN; STATIN; TESAGLITAZAR; TORCETRAPIB; UNCLASSIFIED DRUG;

ANGINA PECTORIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROMA; ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; CORONARY ARTERY SPASM; CORONARY RISK; DIABETES MELLITUS; DISEASE COURSE; FLUSHING; HEART PROTECTION; HOMEOSTASIS; HUMAN; ISCHEMIC HEART DISEASE; LEUKOCYTE ADHERENCE; LIVER TOXICITY; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL TRANSPORT; CHOLESTEROL; CHOLESTEROL, HDL; CORONARY DISEASE; HOMEOSTASIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; OXIDATIVE STRESS; PPAR ALPHA; PPAR DELTA; PPAR GAMMA; QUINOLINES; SULFHYDRYL COMPOUNDS;

EID: 33746766313     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2006.02.003     Document Type: Review

References (149)

1. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 26 (2003) S83-S86
2. Ansell B.J., Watson K.E., Fogelman A.M., Navab M., and Fonarow G.C. High-density lipoprotein function recent advances. J Am Coll Cardiol 46 (2005) 1792-1798
3. Ashen M.D., and Blumenthal R.S. Clinical practice. Low HDL cholesterol levels. N Engl J Med 353 (2005) 1252-1260
4. Assmann G., von Eckardstein A., and Funke H. High density lipoproteins, reverse transport of cholesterol, and coronary artery disease. Insights from mutations. Circulation 87 (1993) III28-III34
5. Assmann G., Schulte H., von Eckardstein A., and Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 124 (1996) S11-S20 (Suppl.)
6. Assmann G., and Gotto Jr. A.M. HDL cholesterol and protective factors in atherosclerosis. Circulation 109 (2004) III8-III14
7. Asztalos B.F., Roheim P.S., Milani R.L., Lefevre M., McNamara J.R., Horvath K.V., et al. Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 20 (2000) 2670-2676
8. Asztalos B.F., Cupples L.A., Demissie S., Horvath K.V., Cox C.E., Batista M.C., et al. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 24 (2004) 2181-2187
9. Asztalos B.F., de la Llera-Moya M., Dallal G.E., Horvath K.V., Schaefer E.J., and Rothblat G.H. Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux. J Lipid Res 46 (2005) 2246-2253
10. Ballantyne C.M., Herd J.A., Ferlic L.L., Dunn J.K., Farmer J.A., Jones P.H., et al. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation 99 (1999) 736-743
11. Ballantyne C.M., Olsson A.G., Cook T.J., Mercuri M.F., Pedersen T.R., and Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 104 (2001) 3046-3051
12. Barzilai N., Atzmon G., Schechter C., Schaefer E.J., Cupples A.L., Lipton R., et al. Unique lipoprotein phenotype and genotype associated with exceptional longevity. Jama 290 (2003) 2030-2040
13. Barter P.J., Baker P.W., and Rye K.A. Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. Curr Opin Lipidol 13 (2002) 285-288
14. Barter P.J., and Rye K.A. Cholesteryl ester transfer protein, high density lipoprotein and arterial disease. Curr Opin Lipidol 12 (2001) 377-382
15. Barter P.J., Brewer Jr. H.B., Chapman M.J., Hennekens C.H., Rader D.J., and Tall A.R. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 23 (2003) 160-167
16. Barter P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., and Fogelman A.M. Antiinflammatory properties of HDL. Circ Res 95 (2004) 764-772
17. Birjmohun R.S., Hutten B.A., Kastelein J.J., and Stroes E.S. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 45 (2005) 185-197
18. Blanche P.J., Gong E.L., Forte T.M., and Nichols A.V. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta 665 (1981) 408-419
19. Bots M., Riley W., Evans G., Kastelein J., Revkin J., Thuren T., et al. Design of a study on the effect of Torcetrapib/Atorvastatin versus Atorvastatin alone on carotid intima-media thickness in patients with mixed Hyperlipidemia [poster]. Poster presented at the. 75th European Atherosclerosis Society congress, Prague, Czech Republic (2005 (23-26 April))
20. Brewer Jr. H.B. Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams. Am J Cardiol 92 (2003) 23K-29K
21. Brewer Jr. H.B., Remaley A.T., Neufeld E.B., Basso F., and Joyce C. Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. Arterioscler Thromb Vasc Biol 24 (2004) 1755-1760
22. Brousseau M.E., Schaefer E.J., Wolfe M.L., Bloedon L.T., Digenio A.G., Clark R.W., et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 350 (2004) 1505-1515
23. Brown B.G., Zhao X.Q., Chait A., Fisher L.D., Cheung M.C., Morse J.S., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 (2001) 1583-1592
24. Bowry V.W., Stanley K.K., and Stocker R. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci U S A 89 (1992) 10316-10320
25. Calabresi L., Gomaraschi M., and Franceschini G. Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler Thromb Vasc Biol 23 (2003) 1724-1731
26. Calabresi L., Vecchio G., Longhi R., Gianazza E., Palm G., Wadensten H., et al. Molecular characterization of native and recombinant apolipoprotein A-IMilano dimer. The introduction of an interchain disulfide bridge remarkably alters the physicochemical properties of apolipoprotein A-I. J Biol Chem 269 (1994) 32168-32174
27. Canner P.L., Berge K.G., Wenger N.K., Stamler J., Friedman L., Prineas R.J., et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 8 (1986) 1245-1255
28. Capuzzi D.M., Morgan J.M., Weiss R.J., Chitra R.R., Hutchinson H.G., and Cressman M.D. Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. Am J Cardiol 91 (2003) 1304-1310
29. Carlson L.A., and Oro L. The effect of nicotinic acid on the plasma free fatty acid; demonstration of a metabolic type of sympathicolysis. Acta Med Scand 172 (1962) 641-645
30. Castelli W.P., Garrison R.J., Wilson P.W., Abbott R.D., Kalousdian S., and Kannel W.B. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. Jama 256 (1986) 2835-2838
31. Chapman M.J. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 171 (2003) 1-13
32. Chapman M.J., Goldstein S., Lagrange D., and Laplaud P.M. A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum. J Lipid Res 22 (1981) 339-358
33. Chapman M.J., Assmann G., Fruchart J.C., Shepherd J., and Sirtori C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid-a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 20 (2004) 1253-1268
34. Clark R.W., Sutfin T.A., Ruggeri R.B., Willauer A.T., Sugarman E.D., Magnus-Aryitey G., et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 24 (2004) 490-497
35. Clark R.W., Ruggeri R.B., Cunningham D., and Bamberger M.J. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lip Res 47 3 (2006) 537-552
36. Cockerill G.W., Huehns T.Y., Weerasinghe A., Stocker C., Lerch P.G., Miller N.E., et al. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation 103 (2001) 108-112
37. Dachet C., Poirier O., Cambien F., Chapman J., and Rouis M. New functional promoter polymorphism, CETP/-629, in cholesteryl ester transfer protein (CETP) gene related to CETP mass and high density lipoprotein cholesterol levels: role of Sp1/Sp3 in transcriptional regulation. Arterioscler Thromb Vasc Biol 20 (2000) 507-515
38. Davidson M., McKenney J., Revkin J., and Shear C. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor torcetrapib when administered with and without atorvastatin to subjects with a low level of high-density lipoprotein cholesterol. Presented at the Annual Scientific Session of the American College of Cardiology, Orlando, Florida (2005 (March 6-9)) 802-803 Presentation
39. De Backer G., Ambrosioni E., Borch-Johnsen K., Brotons C., Cifkova R., Dallongeville J., et al. European guidelines on cardiovascular disease prevention in clinical practice. Executive Summary. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 24 (2003) 1601-1610
40. Decossin C., Tailleux A., Fruchart J.C., and Fievet C. Prevention of in vitro low-density lipoprotein oxidation by an albumin-containing Lp A-I subfraction. Biochim Biophys Acta 1255 (1995) 31-38
41. de Grooth G.J., Kuivenhoven J.A., Stalenhoef A.F., de Graaf J., Zwinderman A.H., Posma J.L., et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 105 (2002) 2159-2165
42. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 366 (2005) 1279-1289
43. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., and Beere P.A. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615-1622
44. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357 (2001) 905-910
45. Epand R.M., Stafford A., Leon B., Lock P.E., Tytler E.M., Segrest J.P., et al. HDL and apolipoprotein A-I protect erythrocytes against the generation of procoagulant activity. Arterioscler Thromb 14 (1994) 1775-1783
46. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III); 2001.
47. Fagerberg B., Edwards S., Halmos T., Lopatynski J., Schuster H., Stender S., et al. Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population. Diabetologia 48 (2005) 1716-1725
48. Fleisher L.N., Tall A.R., Witte L.D., Miller R.W., and Cannon P.J. Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins. J Biol Chem 257 (1982) 6653-6655
49. Franceschini G., Calabresi L., Chiesa G., Parolini C., Sirtori C.R., Canavesi M., et al. Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice. Arterioscler Thromb Vasc Biol 19 (1999) 1257-1262
50. Frick M.H., Elo O., Haapa K., Heinonen O.P., Heinsalmi P., Helo P., et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317 (1987) 1237-1245
51. Fruchart J.C., Staels B., and Duriez P. The role of fibric acids in atherosclerosis. Curr Atheroscler Rep 3 (2001) 83-92
52. Genest Jr. J.J., Martin-Munley S.S., McNamara J.R., Ordovas J.M., Jenner J., Myers R.H., et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 85 (1992) 2025-2033
53. Gotto Jr. A.M., and Brinton E.A. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. J Am Coll Cardiol 43 (2004) 717-724
54. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., and Dawber T.R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 62 (1977) 707-714
55. Gordon D.J., Probstfield J.L., Garrison R.J., Neaton J.D., Castelli W.P., Knoke J.D., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79 (1989) 8-15
56. Goulinet S., and Chapman M.J. Plasma LDL and HDL subspecies are heterogenous in particle content of tocopherols and oxygenated and hydrocarbon carotenoids. Relevance to oxidative resistance and atherogenesis. Arterioscler Thromb Vasc Biol 17 (1997) 786-796
57. Guerin M., Le Goff W., Lassel T.S., Van Tol A., Steiner G., and Chapman M.J. Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol 21 (2001) 282-288
58. Guyton J.R., Goldberg A.C., Kreisberg R.A., Sprecher D.L., Superko H.R., and O'Connor C.M. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 82 (1998) 737-743
59. Haffner S.M. Dyslipidemia management in adults with diabetes. Diabetes Care 27 Suppl. 1 (2004) S68-S71
60. Hajduk S.L., Moore D.R., Vasudevacharya J., Siqueira H., Torri A.F., Tytler E.M., et al. Lysis of Trypanosoma brucei by a toxic subspecies of human high density lipoprotein. J Biol Chem 264 (1989) 5210-5217
61. Hannuksela M., Marcel Y.L., Kesaniemi Y.A., and Savolainen M.J. Reduction in the concentration and activity of plasma cholesteryl ester transfer protein by alcohol. J Lipid Res 33 (1992) 737-744
62. Hansel B., Giral P., Nobecourt E., Chantepie S., Bruckert E., Chapman M.J., et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab 89 (2004) 4963-4971
63. Huang Z., Inazu A., Nohara A., Higashikata T., and Mabuchi H. Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin Sci (Lond) 103 (2002) 587-594
64. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. http://www.idf.org/webdata/docs/IDF_Metasyndrome_definition.pdf. Accessed October 16, 2005.
65. Jin F.Y., Kamanna V.S., and Kashyap M.L. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. Arterioscler Thromb Vasc Biol 17 (1997) 2020-2028
66. Ji Y., Wang N., Ramakrishnan R., Sehayek E., Huszar D., Breslow J.L., et al. Hepatic scavenger receptor BI promotes rapid clearance of high density lipoprotein free cholesterol and its transport into bile. J Biol Chem 274 (1999) 33398-33402
67. Karpe F., and Frayn K.N. The nicotinic acid receptor-a new mechanism for an old drug. Lancet 363 (2004) 1892-1894
68. Kashyap M.L., McGovern M.E., Berra K., Guyton J.R., Kwiterovich P.O., Harper W.L., et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 89 (2002) 672-678
69. Kastelein J., Bots M., Riley W., Evans G., Meijer R., Revkin J., et al. Design of a study comparing Torcetrapib/Atorvastatin with Atorvastatin alone on carotid atherosclerosis in patients with familial Hypercholesterolemia. Poster presented at the. 75th European Atherosclerosis Society Congress, Prague, Czech Republic (2005, 23-26 April)
70. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
71. Kimura T., Sato K., Kuwabara A., Tomura H., Ishiwara M., Kobayashi I., et al. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J Biol Chem 276 (2001) 31780-31785
72. Khovidhunkit W., Kim M.S., Memon R.A., Shigenaga J.K., Moser A.H., Feingold K.R., et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 45 (2004) 1169-1196
73. Knoblauch H., Bauerfeind A., Toliat M.R., Becker C., Luganskaja T., Gunther U.P., et al. Haplotypes and SNPs in 13 lipid-relevant genes explain most of the genetic variance in high-density lipoprotein and low-density lipoprotein cholesterol. Hum Mol Genet 13 (2004) 993-1004
74. Kontush A., Chantepie S., and Chapman M.J. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 23 (2003) 1881-1888
75. Kozyraki R. Cubilin, a multifunctional epithelial receptor: an overview. J Mol Med 79 (2001) 161-167
76. Kuivenhoven J.A., de Grooth G.J., Kawamura H., Klerkx A.H., Wilhelm F., and Kastelein J.J.P. Inhibition of cholesteryl ester transfer protein by JJT-705 in combination with pravastatin in type II dyslipidemia. Venice, Italy: Presentation at the XV International Symposium on Drugs Affecting Lipid Metabolism (2004)
77. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
78. Lawn R.M., Wade D.P., Garvin M.R., Wang X., Schwartz K., Porter J.G., et al. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest 104 (1999) R25-R31
79. Le Goff W., Guerin M., and Chapman M.J. Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. Pharmacol Ther 101 (2004) 17-38
80. Lewis G.F., and Rader D.J. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 96 (2005) 1221-1232
81. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation 105 (2002) 1135-1143
82. Ljung B., Bamberg K., Dahllof B., Kjellstedt A., Oakes N.D., Ostling J., et al. AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats. J Lipid Res 43 (2002) 1855-1863
83. Mackness M.I., Durrington P.N., and Mackness B. How high-density lipoprotein protects against the effects of lipid peroxidation. Curr Opin Lipidol 11 (2000) 383-388
84. Mackness B., Durrington P., McElduff P., Yarnell J., Azam N., Watt M., et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 107 (2003) 2775-2779
85. Mackness B., Hine D., Liu Y., Mastorikou M., and Mackness M. Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem Biophys Res Commun 318 (2004) 680-683
86. Maeda K., Noguchi Y., and Fukui T. The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis. Prev Med 37 (2003) 283-290
87. Mineo C., Yuhanna I.S., Quon M.J., and Shaul P.W. High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem 278 (2003) 9142-9149
88. Miyazaki Y., Mahankali A., Matsuda M., Glass L., Mahankali S., Ferrannini E., et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24 (2001) 710-719
89. Morehouse L.A., Sugarman E.D., Bourassa P.A., and Milici A.J. The CETP-inhibitor torcetrapib raises HDL and prevents aortic atherosclerosis in rabbits. Presentation at the. XV International Symposium on Drugs Affecting Metabolism (2004)
90. Mosca L., Appel L.J., Benjamin E.J., Berra K., Chandra-Strobos N., and Fabunmi R.P. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 109 (2004) 672-693
91. Navab M., Imes S.S., Hama S.Y., Hough G.P., Ross L.A., Bork R.W., et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 88 (1991) 2039-2046
92. Navab M., Hama S.Y., Anantharamaiah G.M., Hassan K., Hough G.P., Watson A.D., et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 41 (2000) 1495-1508
93. Navab M., Berliner J.A., Subbanagounder G., Hama S., Lusis A.J., Castellani L.W., et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 21 (2001) 481-488
94. Navab M., Anantharamaiah G.M., Reddy S.T., Hama S., Hough G., Grijalva V.R., et al. Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol 25 (2005) 1325-1331
95. Nicholls S.J., Dusting G.J., Cutri B., Bao S., Drummond G.R., Rye K.A., et al. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 111 (2005) 1543-1550
96. Nicholls S.J., Zheng L., and Hazen S.L. Formation of dysfunctional high-density lipoprotein by myeloperoxidase. Trends Cardiovasc Med 15 (2005) 212-219
97. Nissen S.E., Tsunoda T., Tuzcu E.M., Schoenhagen P., Cooper C.J., Yasin M., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290 (2003) 2292-2300
98. Nissen S.E., Tardif J.-C., Crowe T., Ennis M., Thuren T., Shear C.L., et al. Design of a study comparing Torcetrapib/Atorvastatin with atorvastatin alone on Atheroma volume in patients with coronary heart disease [poster]. Poster presented at the. 75th European Atherosclerosis Society Congress, Prague, Czech Republic (2005 (23-26 April))
99. Nobecourt E., Jacqueminet S., Hansel B., Chantepie S., Grimaldi A., Chapman M.J., et al. Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. Diabetologia 48 (2005) 529-538
100. Nofer J.R., Levkau B., Wolinska I., Junker R., Fobker M., von Eckardstein A., et al. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem 276 (2001) 34480-34485
101. Nofer J.R., van der Giet M., Tolle M., Wolinska I., von Wnuck Lipinski K., Baba H.A., et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 113 (2004) 569-581
102. Ohara Y., Peterson T.E., and Harrison D.G. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 91 (1993) 2546-2551
103. Okamoto H., Yonemori F., Wakitani K., Minowa T., Maeda K., and Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406 (2000) 203-207
104. Oliver Jr. W.R., Shenk J.L., Snaith M.R., Russell C.S., Plunket K.D., Bodkin N.L., et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A 98 (2001) 5306-5311
105. Rader D.J., and Dugi K.A. The endothelium and lipoproteins: insights from recent cell biology and animal studies. Semin Thromb Hemost 26 (2000) 521-528
106. Raskin P., Rendell M., Riddle M.C., Dole J.F., Freed M.I., and Rosenstock J. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 24 (2001) 1226-1232
107. Reddy S.T., Anantharamaiah G.M., Navab M., Hama S., Hough G., Grijalva V., et al. Oral amphipathic peptides as therapeutic agents. Expert Opin Investig Drugs 15 (2006) 13-21
108. Robins S.J., Collins D., Wittes J.T., Papademetriou V., Deedwania P.C., Schaefer E.J., et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 285 (2001) 1585-1591
109. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
110. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341 (1999) 410-418
111. Rubic T., Trottmann M., and Lorenz R.L. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol 67 (2004) 411-419
112. Sacks F.M. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 90 (2002) 139-143
113. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J 335 (1996) 1001-1009
114. Schaefer J.R., Schweer H., Ikewaki K., Stracke H., Seyberth H.J., Kaffarnik H., et al. Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. Atherosclerosis 144 (1999) 177-184
115. Schwartz C.C., VandenBroek J.M., and Cooper P.S. Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans. J Lipid Res 45 (2004) 1594-1607
116. Sharrett A.R., Ballantyne C.M., Coady S.A., Heiss G., Sorlie P.D., Catellier D., et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 104 (2001) 1108-1113
117. Shepherd J., Packard C.J., Patsch J.R., Gotto Jr. A.M., and Taunton O.D. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest 63 (1979) 858-867
118. Shih D.M., Gu L., Hama S., Xia Y.R., Navab M., Fogelman A.M., et al. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest 97 (1996) 1630-1639
119. Shih D.M., Gu L., Xia Y.R., Navab M., Li W.F., Hama S., et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394 (1998) 284-287
120. Spate-Douglas T., and Keyser R.E. Exercise intensity: its effect on the high-density lipoprotein profile. Arch Phys Med Rehabil 80 (1999) 691-695
121. Spiegelman B.M. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47 (1998) 507-514
122. Spieker L.E., Sudano I., Hurlimann D., Lerch P.G., Lang M.G., Binggeli C., et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 105 (2002) 1399-1402
123. Sprecher D., Massien C., Patterson S., Zalenski A., and Johnson A. HDL-C effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist. AHA Congress (2004)
124. Standards of medical care in diabetes. Diabetes Care 28 (2005) S4-S36
125. Sugatani J., Miwa M., Komiyama Y., and Ito S. High-density lipoprotein inhibits the synthesis of platelet-activating factor in human vascular endothelial cells. J Lipid Mediat Cell Signal 13 (1996) 73-88
126. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 269 (1993) 3015-3023
127. Tall A.R. Plasma cholesteryl ester transfer protein. J Lipid Res 34 (1993) 1255-1274
128. Taylor A.J., Sullenberger L.E., Lee H.J., Lee J.K., and Grace K.A. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110 (2004) 3512-3517
129. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
130. Therond P., Bonnefont-Rousselot D., Laureaux C., Vasson M.P., Motta C., Legrand A., et al. Copper oxidation of in vitro dioleolylphosphatidylcholine-enriched high-density lipoproteins: physicochemical features and cholesterol effluxing capacity. Arch Biochem Biophys 362 (1999) 139-147
131. The Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 345 (1995) 1274-1275
132. Thompson M.M., Reed S.C., and Cockerill G.W. Therapeutic approaches to raising plasma HDL-cholesterol levels. Nat Clin Pract 1 (2004) 84-89
133. Toth P.P. Reverse cholesterol transport: high-density lipoprotein's magnificent mile. Curr Atheroscler Rep 5 (2003) 386-393
134. Ulevitch R.J., Johnston A.R., and Weinstein D.B. New function for high density lipoproteins. Their participation in intravascular reactions of bacterial lipopolysaccharides. J Clin Invest 64 (1979) 1516-1524
135. Vakkilainen J., Steiner G., Ansquer J.C., Aubin F., Rattier S., Foucher C., et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 107 (2003) 1733-1737
136. Viswambharan H., Ming X.F., Zhu S., Hubsch A., Lerch P., Vergeres G., et al. Reconstituted high-density lipoprotein inhibits thrombin-induced endothelial tissue factor expression through inhibition of RhoA and stimulation of phosphatidylinositol 3-kinase but not Akt/endothelial nitric oxide synthase. Circ Res 94 (2004) 918-925
137. Wallace J.M., Schwarz M., Coward P., Houze J., Sawyer J.K., Kelley K.L., et al. Effects of peroxisome proliferator-activated receptor alpha/delta agonists on HDL-cholesterol in vervet monkeys. J Lipid Res 46 (2005) 1009-1016
138. Wang M., and Briggs M.R. HDL: the metabolism, function, and therapeutic importance. Chem Rev 104 (2004) 119-137
139. Wang N., Lan D., Chen W., Matsuura F., and Tall A.R. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci U S A 101 (2004) 9774-9779
140. Weissberg P.L. Atherogenesis: current understanding of the causes of atheroma. Heart 83 (2000) 247-252
141. Whitney E.J., Krasuski R.A., Personius B.E., Michalek J.E., Maranian A.M., Kolasa M.W., et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 142 (2005) 95-104
142. Williams D.L., Connelly M.A., Temel R.E., Swarnakar S., Phillips M.C., de la Llera-Moya M., et al. Scavenger receptor BI and cholesterol trafficking. Curr Opin Lipidol 10 (1999) 329-339
143. Wilsgaard T., and Arnesen E. Change in serum lipids and body mass index by age, sex, and smoking status: the Tromso study 1986-1995. Ann Epidemiol 14 (2004) 265-273
144. Wolfe M.L., Vartanian S.F., Ross J.L., Bansavich L.L., Mohler III E.R., Meagher E., et al. Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. Am J Cardiol 87 (2001) 476-479, A477
145. Yancey P.G., Bortnick A.E., Kellner-Weibel G., de la Llera-Moya M., Phillips M.C., and Rothblat G.H. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 23 (2003) 712-719
146. Young S.G., and Parthasarathy S. Why are low-density lipoproteins atherogenic?. West J Med 160 (1994) 153-164
147. Yuhanna I.S., Zhu Y., Cox B.E., Hahner L.D., Osborne-Lawrence S., Lu P., et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med 7 (2001) 853-857
148. Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lanas F., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 (2004) 937-952
149. Zhang Y., Zanotti I., Reilly M.P., Glick J.M., Rothblat G.H., and Rader D.J. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation 108 (2003) 661-663